🇺🇸 FDA
Pipeline program

Venclyxto 100 mg film-coated tablets, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, BGB-16673, BGB-16673, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Zydelig 150 mg film-coated tablets, Zydelig 100 mg film-coated tablets

BGB-16673-302

Phase 3 small_molecule active

Quick answer

Venclyxto 100 mg film-coated tablets, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, BGB-16673, BGB-16673, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Zydelig 150 mg film-coated tablets, Zydelig 100 mg film-coated tablets for Chronic lymphotic leukemia and Small Lymphocytic lymphoma is a Phase 3 program (small_molecule) at Beone Medicines Ireland Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Beone Medicines Ireland Limited
Indication
Chronic lymphotic leukemia and Small Lymphocytic lymphoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials